CD70 and ovarian cancer: Although SGN‐75 showed significant antitumour activity in pancreatic and ovarian cancer models, the first‐in‐human NCT01015911 study recruiting CD70‐positive metastatic RCC and non‐Hodgkin lymphoma (NHL) sufferers revealed that its clinical efficacy did not meet expectations.